382 related articles for article (PubMed ID: 20375007)
1. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.
Wei CJ; Boyington JC; Dai K; Houser KV; Pearce MB; Kong WP; Yang ZY; Tumpey TM; Nabel GJ
Sci Transl Med; 2010 Mar; 2(24):24ra21. PubMed ID: 20375007
[TBL] [Abstract][Full Text] [Related]
2. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
3. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
4. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
[TBL] [Abstract][Full Text] [Related]
5. Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity.
Hervé PL; Lorin V; Jouvion G; Da Costa B; Escriou N
Virology; 2015 Dec; 486():134-45. PubMed ID: 26433051
[TBL] [Abstract][Full Text] [Related]
6. Neutralization and Binding Profile of Monoclonal Antibodies Generated Against Influenza A H1N1 Viruses.
Shembekar N; Mallajosyula VV; Malik A; Saini A; Varadarajan R; Gupta SK
Monoclon Antib Immunodiagn Immunother; 2016 Aug; 35(4):191-8. PubMed ID: 27463230
[TBL] [Abstract][Full Text] [Related]
7. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.
Liu X; Liu Y; Zhang Y; Chen Z; Tang Z; Xu Q; Wang Y; Zhao P; Qi Z
PLoS One; 2013; 8(3):e58810. PubMed ID: 23527030
[TBL] [Abstract][Full Text] [Related]
8. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
[TBL] [Abstract][Full Text] [Related]
9. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
10. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
Klimova RR; Masalova OV; Burtseva EI; Chichev EV; Lesnova EI; Oskerko TA; Mukasheva EA; Rudneva IA; Lvov DK; Kushch AA
Vopr Virusol; 2011; 56(3):15-20. PubMed ID: 21786621
[TBL] [Abstract][Full Text] [Related]
11. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
Li GM; Chiu C; Wrammert J; McCausland M; Andrews SF; Zheng NY; Lee JH; Huang M; Qu X; Edupuganti S; Mulligan M; Das SR; Yewdell JW; Mehta AK; Wilson PC; Ahmed R
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):9047-52. PubMed ID: 22615367
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.
Xu R; Ekiert DC; Krause JC; Hai R; Crowe JE; Wilson IA
Science; 2010 Apr; 328(5976):357-60. PubMed ID: 20339031
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
15. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
16. The influenza virus hemagglutinin head evolves faster than the stalk domain.
Kirkpatrick E; Qiu X; Wilson PC; Bahl J; Krammer F
Sci Rep; 2018 Jul; 8(1):10432. PubMed ID: 29992986
[TBL] [Abstract][Full Text] [Related]
17. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
18. Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses.
Haveri A; Ikonen N; Kantele A; Anttila VJ; Ruotsalainen E; Savolainen-Kopra C; Julkunen I
Vaccine; 2019 May; 37(20):2731-2740. PubMed ID: 30954308
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin.
Schmeisser F; Friedman R; Besho J; Lugovtsev V; Soto J; Wang W; Weiss C; Williams O; Xie H; Ye Z; Weir JP
Influenza Other Respir Viruses; 2013 May; 7(3):480-90. PubMed ID: 23122228
[TBL] [Abstract][Full Text] [Related]
20. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
